Chronic Lymphocytic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Preliminary Assessment of [18F]BL40 in PET/CT Scans
Conditions: Diffuse Large B-cell Lymphoma; Multiple Myeloma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Waldenstr öm Macroglobulinemia Interventions: Diagnostic Test: 18F-BL40 PET/CT; Diagnostic Test: 18F-FDG PET/CT; Diagnostic Test: Routine Blood Draw - Phase 1 only Sponsors: British Columbia Cancer Agency Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

A Prospective Study of Hypertension and Arrhythmias in CLL Patients Treated With Bruton's Tyrosine Kinase Inhibitors
Conditions: Chronic Lymphocytic Leukemia; Atrial Fibrillation; Hypertension; Cardiotoxicity Interventions: Other: no intervention Sponsors: Abramson Cancer Center at Penn Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

Acalabrutinib Real World Italian obSErvational Study -ARISE
Conditions: Chronic Lymphocytic Leukemia Interventions: Drug: acalabrutinib Sponsors: AstraZeneca; Yghea Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell Interventions: Biological: Liso-cel; Drug: Idelalisib; Drug: Rituximab; Drug: Bendamustine; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Conditions: B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia Interventions: Biological: Autologous BAFFR-tar...
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials

REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
Conditions: Chronic Lymphocytic Leukemia Interventions: Drug: Non interventional study Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Conditions: Chronic Lymphocytic Leukemia; Hematopoietic and Lymphoid System Neoplasm; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma Interventions: Drug: Nemtabrutinib; Drug: Ibrutinib; Drug: Acalabrutinib Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Conditions: Chronic Lymphocytic Leukemia Sponsors: AbbVie Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression
Conditions: Chronic Lymphocytic Leukemia Interventions: Other: Observation Sponsors: Gruppo Italiano Malattie EMatologiche dell ' Adulto Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Conditions: CLL Interventions: Drug: Sonrotoclax; Drug: Zanubrutinib; Drug: Venetoclax; Drug: Obinutuzumab Sponsors: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Hodgkin Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Procedure: Biospecimen Collection; Drug: Granulocyte Colony-Stimulating Factor; Drug: Hematopoietic Cell Transplantation Conditioning Regimen; Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; Procedure: Pheresis; Drug: Placebo Administration; ...
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia Intervention: Drug: Loncastuximab Tesirine Sponsors: Mayur Narkhede; ADC Therapeutics S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials